The rationale for using apoA-I as a clinical marker of cardiovascular risk.
An inverse relationship between the concentration of high-density lipoprotein (HDL) cholesterol and the risk of developing cardiovascular is well established. There are several documented functions of HDLs that may contribute to a protective role of these lipoproteins. These include the ability of HDLs to promote the efflux of cholesterol from macrophages and foam cells in the artery wall and to anti-inflammatory/antioxidant properties of these lipoproteins. The fact that the main apolipoprotein of HDLs, apoA-I, plays a prominent role in each of these functions adds support to the view that apoA-I should be measured as a component of the assessment of cardiovascular risk in humans.
Barter
P J
PJ
The Heart Research Institute, Sydney, Australia. barterp@hri.org.au
Rye
K-A
KA
D000893:Anti-Inflammatory Agents / Q000378:metabolism; D000975:Antioxidants / Q000378:metabolism; D016632:Apolipoprotein A-I / Q000097:blood*; D050197:Atherosclerosis / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000175:diagnosis*; D002784:Cholesterol / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism; D006801:Humans; D008075:Lipoproteins, HDL / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D018570:Risk Assessment / Q000379:methods
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D016632:Apolipoprotein A-I; D015415:Biomarkers; D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D002784:Cholesterol